Publication:
Prevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid: The PREDIABOLE study, a randomized controlled trial.

dc.contributor.authorSantos-Lozano, José M
dc.contributor.authorRada, Mirela
dc.contributor.authorLapetra, José
dc.contributor.authorGuinda, Ángeles
dc.contributor.authorJiménez-Rodríguez, María C
dc.contributor.authorCayuela, José A
dc.contributor.authorÁngel-Lugo, Antonio
dc.contributor.authorVilches-Arenas, Ángel
dc.contributor.authorGómez-Martín, Ana M
dc.contributor.authorOrtega-Calvo, Manuel
dc.contributor.authorCastellano, José M
dc.date.accessioned2023-01-25T13:38:16Z
dc.date.available2023-01-25T13:38:16Z
dc.date.issued2019-08-28
dc.description.abstractTo assess whether the regular intake of an oleanolic acid (OA)-enriched olive oil is effective in the prevention of diabetes. In the PREDIABOLE study, prediabetic individuals (impaired fasting glucose and impaired glucose tolerance) of both sexes (176 patients, aged 30-80 years) were randomized to receive 55 mL/day of OA-enriched olive oil (equivalent dose 30 mg OA/day) [intervention group (IG)] or the same oil not enriched [control group (CG)]. The main outcome was the incidence of new-onset type 2 diabetes in both groups. Forty-eight new diabetes cases occurred, 31 in the CG and 17 in the IG. The multivariate-adjusted hazard ratio was 0.45 (95% CI, 0.24-0.83) for the IG compared with the CG. Intervention-related adverse effects were not reported. The intake of OA-enriched olive oil reduces the risk of developing diabetes in prediabetic patients. The results of the PREDIABOLE study promote the use of OA in new functional foods and drugs for the prevention of diabetes in individuals at risk of developing it.
dc.identifier.doi10.1111/dom.13838
dc.identifier.essn1463-1326
dc.identifier.pmid31364228
dc.identifier.unpaywallURLhttps://digital.csic.es/bitstream/10261/198205/1/PostP_2019_DOM_V21_P2526.pdf
dc.identifier.urihttp://hdl.handle.net/10668/14343
dc.issue.number11
dc.journal.titleDiabetes, obesity & metabolism
dc.journal.titleabbreviationDiabetes Obes Metab
dc.language.isoen
dc.organizationFundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla-FISEVI
dc.organizationSevilla
dc.organizationFundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla-FISEVI
dc.page.number2526-2534
dc.pubmedtypeJournal Article
dc.pubmedtypeRandomized Controlled Trial
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectantidiabetic drug
dc.subjectoleanolic acid
dc.subjectphase I-II study
dc.subjectprimary care
dc.subjectrandomized trial
dc.subjecttype 2 diabetes
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshDouble-Blind Method
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHypoglycemic Agents
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshOleanolic Acid
dc.subject.meshOlive Oil
dc.subject.meshPrediabetic State
dc.titlePrevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid: The PREDIABOLE study, a randomized controlled trial.
dc.typeresearch article
dc.type.hasVersionAM
dc.volume.number21
dspace.entity.typePublication

Files